Embelin ameliorates dextran sodium sulfate-induced colitis in mice

International Immunopharmacology

Volumn 11, Issue 6, 2011, Pages 724-731

  Kumar G , Kalyan ^a,e   Dhamotharan R , ^a   Kulkarni, Nagaraj M ^b   Honnegowda, Srinivasa ^c   Murugesan S , ^d  

^a PRESIDENCY COLLEGE   (India)

^b K L E S S COLLEGE OF PHARMACY   (India)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Pachaiyaappa's College   (India)

^e Kemin Industries Inc   (United States)

Author keywords

Cytokines; DSS; Embelin; Ulcerative colitis

Indexed keywords

DEXTRAN SULFATE; EMBELIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESALAZINE; MESSENGER RNA; MYELOPEROXIDASE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; COLON; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; MALE; MEDIATOR; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCORING SYSTEM; SPLEEN SIZE; TREATMENT DURATION; ULCERATIVE COLITIS; WEIGHT REDUCTION;

ANIMALS; BENZOQUINONES; COLITIS, ULCERATIVE; CYTOKINES; DEXTRAN SULFATE; DISEASE PROGRESSION; FRUIT; INFLAMMATION MEDIATORS; MICE; MICE, INBRED BALB C; MYRSINACEAE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASE; PHYTOTHERAPY;

EID: 79955788047     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.01.022     Document Type: Article

References (45)

1. Ardizzone and Bianchi Porro. Biologic therapy for inflammatory bowel disease. Drugs 2005;65:2253-86.
2. Asakura H. Ulcerative colitis and intestinal bleeding. Nippon Rinsho 1998;56:2354-9.
3. Bischoff S, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 1999;44:643-52. (Pubitemid 29195911)
4. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999;11:648.
5. Boughton-Smith N. Pathological and therapeutic implications for nitric oxide in inflammatory bowel disease. J R Soc Med 1994;87:312-4.
6. Chitra M, Sukumar E, Suja V, Devi CS. Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy 1994;40:109-13.
7. Colon A, Menchen LA, Hurtado O, De Cristobal J, Lizasoain I, Leza JC, et al. Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis. Cytokine 2001;16:220-6. (Pubitemid 34252604)
8. Cross R, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 2003;9:179-89. (Pubitemid 36592449)
9. Cuzzocrea S. Emerging biotherapies for inflammatory bowel disease. Expert Opin Emerg Drugs 2003;8:339-47. (Pubitemid 37522655)
10. Dallacker F, Lohnert G. Derivatives of methylene dioxybenzene, a novel synthesis of 3,6 dihydroxy-2-ethyl-1,4-benzoquinone, embelin, vilangin, rapanone, dihydromaesa quinone, bhogatin, spinulosin and oosporein. Chem Ber 1972;105:614-24.
11. Dieleman L, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Experi mental Immunol 1998;114:385-91. (Pubitemid 28539597)
12. Dionne S, D'Agata ID, Hiscott J, Vanounou T, Seidman EG. Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 1998;112:385-91.
13. Du Y, Wie JS. Study of vermifuges. Isolation of embelin from the fruit of mugua-wha( Embelia oblongifolia hems). Yao Xue Xue Bao 1963;10:578-80.
14. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-5.
15. Gupta Ali MM, Ray Ghatak BJ, Atal CK. Some pharmacological investigations of embelin and its semi synthetic derivatives. Indian J Physiol Pharmacol 1977;21:31-9. (Pubitemid 8082311)
16. Guslandi M. Nitric oxide and inflammatory bowel diseases. European Journal of Clinical Investigation; 28:904-907.
17. Guy-Grand D, DiSanto JP, Henchoz P, Malassis-Seris M, Vassalli P. Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-gamma, TNF) in the induction of epithelial cell death and renewal. Eur J Immunol 1998;28:730-44. (Pubitemid 28101750)
18. Hanauer S. Inflammatory bowel disease. N Engl J Med 1996;334:841-8. (Pubitemid 26099608)
19. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-85.
20. Islam M, Murata T, Fujisawa M, Nagasaka R, Ushio H, Bari AM, et al. Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice. Br J Pharmacol 2008;154:812-24. (Pubitemid 351821588)
21. Kankuri E, Hamalainen M, Hukkanen M, Salmenpera P, Kivilaakso E, Vapaatalo H, et al. Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis. Scand J Gastroenterol 2003;38:186-92. (Pubitemid 36349931)
22. Kankuri E, Vaali K, Knowles RG, Lahde M, Korpela R, Vapaatalo H, et al. Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine. J Pharmacol Exp Ther 2001;298:1128-32. (Pubitemid 32761929)
23. Krieglstein C, Cerwinka WH, Laroux FS, Salter JW, Russell JM, Schuermann G, et al. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J Exp Med 2001;194:1207-18. (Pubitemid 33055040)
24. Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease radicals or ridiculous? Aliment Pharmacol Ther 2002;16:1997-2015.
25. Kwon K, Murakami A, Hayashi R, Ohigashi H. Interleukin-1beta tar- gets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun 2005;337:647-54. (Pubitemid 41429334)
26. Lawson M, Thomas AG, Akobeng AK. Tumor necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3:CD005112.
27. Lee S, LimKT. Glycoprotein isolated from Ulmus davidiana Nakai regulates expression of iNOS and COX-2 in vivo and in vitro. Food Chem Toxicol 2007;45:990-1000.
28. Levin A, Shibolet O. Infliximab in ulcerative colitis. Biologics 2008;2:379-88.
29. Malle E, Furtmuller PG, Sattler W, Obinger C. Myeloperoxidase: a target for new drug development? Br J Pharmacol 2007;152:838-54.
30. Neuman M. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroenterol 2004;13:309-16. (Pubitemid 40103498)
31. Nilsen EM, Johansen FE, Jahnsen FL, Lundin KE, Scholz T, Brandtzaeg P, et al. Cytokine profiles of cultured microvascular endothelial cells from the human intestine. Gut 1998;42:635-42. (Pubitemid 28261048)
32. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702. (Pubitemid 20069706)
33. Pullman W, Elsbury S, Kobayashi M, Hapel AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992;102:529-37.
34. Rojas-Cartagena C, Flores I, Appleyard CB. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine 2005;32:85-93. (Pubitemid 41563038)
35. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med 2000;11:191-6.
36. Sartor R. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:11S.
37. Sreepriya MaB G. Chemopreventive effects of embelin and curcumin against N-nitroso diethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats. Fitoterapia 2005;76:549-55.
38. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-500.
39. Tanaka FK, Ochi M, Tanigawa T, Watanabe T, Fujiwara Y, Ohta K, et al. Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitisvia anti-inflammatory action in damaged tissue in rats. Life Sci 2008;83:771-9.
40. Tountas N, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 1999;117:806-13. (Pubitemid 29468222)
41. Vuorelaa PLM, Saikkuc P, Tammelaa P, Rauhad JP, Wennberge T, Vuorela H. Natural products in the process of finding new drug candidates. Curr Med Chem 2004;11:1375-89. (Pubitemid 38735784)
42. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007;59:1073-83. (Pubitemid 47615208)
43. Xu C, Meng SY, Pan BR. Drug therapy for ulcerative colitis. World J Gastroenterol 2004;10:2311-7. (Pubitemid 39157750)
44. Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ, Lee KT. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW264.7 macrophages. Eur J Pharmacol 2008;584:175-84.
45. Kim YH, Kwon HS, Kim DH, Shin EK, Kang YH, Park JH, Shin HK, Kim JK. 3,3- Diindolylmethane attenuates colonic inflammation and tumorigenesis in mice. Inflamm Bowel Dis 2009;15:1164-73.